Rankings
▼
Calendar
EBS FY 2023 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena
EBS
Emergent BioSolutions Inc.
$446M
FY 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$1.0B
-6.1% YoY
Gross Profit
$360M
34.3% margin
Operating Income
-$726M
-69.2% margin
Net Income
-$761M
-72.5% margin
EPS (Diluted)
$-14.85
Cash Flow
Operating Cash Flow
-$206M
Free Cash Flow
-$258M
Stock-Based Comp.
$23M
Balance Sheet
Total Assets
$1.8B
Total Liabilities
$1.2B
Stockholders' Equity
$649M
Cash & Equivalents
$112M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1.0B
$1.1B
-6.1%
Gross Profit
$360M
$473M
-23.9%
Operating Income
-$726M
-$170M
-327.3%
Net Income
-$761M
-$212M
-259.4%
← Q4 2022
All Quarters
Q1 2023 →